Ayurveda pharmacovigilance has become a major national discussion in India after the National Symposium on Pharmacovigilance in Ayurveda, held in Bengaluru on 17–18 September 2026. The programme focused on adverse reactions to Ayurvedic medicines, herb–drug interactions in chronic disease, safety and standardisation of Rasaushadhi, polypharmacy, integrative-care interactions and under-reported adverse events in long-term noncommunicable disease care [1].
The event is important because many patients now use Ayurveda along with medicines for diabetes, hypertension, heart disease, cancer, autoimmune disease, neurological illness and chronic infections. In such cases, safety cannot be judged only by whether a medicine is natural or traditional. The more relevant clinical question is whether the formulation is suitable for that patient, at that dose, for that duration, with the medicines already being taken [2–5].
Post-event reporting on 20 September 2026 quoted CCRAS Director General Dr Rabinarayan Acharya calling for stronger scientific evidence, pharmacovigilance and translation of Ayurveda research into validated technologies [2]. This reflects a wider movement toward evidence-backed Ayurveda, where classical knowledge is supported by documentation, safety monitoring, interaction assessment and quality-controlled formulations.
What Ayurveda Pharmacovigilance Means
Pharmacovigilance means the scientific detection, assessment, understanding and prevention of adverse effects or other medicine-related problems [3]. In Ayurveda, it includes suspected adverse reactions to herbal medicines, herbo-mineral preparations, poor-quality products, contamination, unsuitable dosing, incorrect patient selection and possible interactions with conventional medicines.
An adverse event during treatment does not automatically prove that the Ayurvedic medicine caused harm. A patient may develop symptoms because of disease progression, infection, food-related illness, another drug, organ dysfunction or a true reaction to the formulation. At the same time, the absence of a complaint does not prove complete safety. Pharmacovigilance helps document the timeline, dose, formulation, other medicines and clinical findings so that the cause can be assessed more responsibly [3].
A proper Ayurvedic prescription should consider Prakriti, disease stage, Agni, Bala, current medicines and laboratory findings. Agni means digestive and metabolic capacity. Bala means the patient’s physical strength, immunity and tolerance capacity. When these are weak, even a good formulation may need dose adjustment, slower introduction or closer monitoring.
Why Herb–Drug Interactions Matter in Chronic Disease
Herb–drug interactions can occur when an herbal or Ayurvedic preparation changes the effect, absorption, metabolism or elimination of another medicine [4]. This may increase the effect of a drug, reduce its effect or create unexpected toxicity.
This becomes especially important in patients taking medicines for diabetes, blood pressure, blood thinning, cancer, epilepsy, transplant care, autoimmune disease or chronic infections. These medicines often need stable blood levels or careful clinical monitoring. Adding a strong herbal or herbo-mineral formulation without reviewing the full medicine list can increase risk.
WHO guidance on herbal medicine interactions explains that interactions may be harmful, beneficial or clinically insignificant depending on the herb, drug, dose, patient condition and duration of use [4]. This means that safety decisions should not be generic. The same herb may be suitable for one patient but unsuitable for another patient who has liver disease, kidney disease, low body weight or a high-risk prescription medicine.
A Human Example: Curcumin, Piperine and Tamoxifen
A human pharmacokinetic study evaluated curcumin, with or without piperine, in patients taking tamoxifen. In the study, curcumin combined with piperine reduced exposure to endoxifen, an active tamoxifen metabolite, by about 12.4% [6].
This study did not prove worse cancer survival, and it does not mean that ordinary dietary turmeric is the same as high-dose curcumin supplements. However, it shows why concentrated herbal extracts and supplements should be reviewed carefully in cancer patients. A patient taking tamoxifen should not add high-dose curcumin or piperine supplements without discussing it with the treating oncology team [6].
Why Polypharmacy Increases Safety Risk
Polypharmacy means using multiple medicines at the same time. Many chronic disease patients take several medicines daily, including prescription drugs, supplements, painkillers, antacids, sleep medicines, vitamins and herbal products. The risk is not only the number of medicines. The real concern is whether the combination remains suitable for that patient [5].
WHO’s medication safety report on polypharmacy emphasises person-centred medicine review, especially in people with multiple long-term conditions [5]. This applies directly to integrative Ayurveda care. Before starting a strong Rasayana, Rasaushadhi or multi-herbal medicine, the doctor should know what the patient is already taking, which medicines are essential, which medicines can interact and which laboratory tests need monitoring.
Rasayana means rejuvenative and restorative Ayurvedic therapy used to support tissue strength, immunity, recovery and long-term resilience. Rasayana therapy can be powerful, but it still requires proper patient selection, dose discipline and follow-up.
Herbo-Mineral Medicine Safety Needs Product-Specific Evidence
Rasaushadhi refers to Ayurvedic herbo-mineral formulations prepared according to Rasashastra principles. These medicines may contain processed mineral or metal-derived ingredients after classical purification and processing. Their safety discussion should be scientific, not fear-based and not blindly defensive.
A widely cited JAMA study tested 193 Ayurvedic products purchased online in 2005. Detectable lead, mercury or arsenic was found in 20.7% of products. Rasa shastra products had a higher prevalence than non-rasa shastra products, and all metal-containing products exceeded at least one acceptable daily-intake standard used by the researchers [7].
This study does not represent every Ayurvedic medicine or every regulated formulation in 2026. It was based on a specific group of internet-purchased products. Still, it strongly supports the need for batch testing, raw material control, finished-product analysis, correct processing and transparent quality documentation [7,8].
Plant-Only Ayurvedic Products Also Need Monitoring
Safety concerns are not limited to herbo-mineral preparations. Plant-only medicines and supplements can also cause adverse reactions in susceptible patients, especially when used in high doses, used for long periods or combined with other medicines.
A case series published in Liver International described five patients with liver injury associated with ashwagandha-containing supplements. The cases mainly showed cholestatic or mixed liver injury, and patients with available follow-up recovered after stopping the suspected product [9].
This does not mean ashwagandha is unsafe for every patient. It means that even familiar herbs need proper indication, correct dose, product quality and clinical monitoring. No herbal product should be considered automatically safe for every patient simply because it is plant-based.
What Patients Should Tell Their Ayurveda Doctor
Patients should inform their Ayurveda doctor about every medicine they take. This includes prescription drugs, Ayurvedic medicines, supplements, imported capsules, protein powders, over-the-counter painkillers, antacids, sleep medicines, blood thinners and medicines taken only occasionally.
The doctor should also know about liver disease, kidney disease, pregnancy, cancer treatment, blood-thinner use, autoimmune disease, allergies, previous drug reactions and recent hospitalisation. These details can change the dose, duration, formulation choice or monitoring plan.
In chronic disease care, recent blood reports are often useful. Depending on the case, these may include CBC, liver function test, kidney function test, fasting glucose, HbA1c, lipid profile, inflammatory markers, coagulation profile or disease-specific markers. The test list should be selected according to the disease and the treatment plan.
When a Reaction Should Not Be Ignored
Some symptoms should never be dismissed as a detox reaction. Breathing difficulty, swelling of the lips or face, fainting, chest pain, severe bleeding, confusion, seizures, yellow eyes, dark urine, severe vomiting, severe abdominal pain, reduced urination or sudden weakness need urgent medical assessment.
If a suspected reaction occurs, the patient should keep the medicine package, prescription, batch number, dose details and symptom timeline. These details help doctors assess whether the event may be related to the formulation, another medicine, the disease itself or another cause.
India’s Ayush Suraksha portal, launched by the Ministry of Ayush on 30 May 2025, provides a formal reporting route for suspected adverse drug reactions and misleading advertisements related to Ayush products [10]. Reporting a suspected reaction does not prove that a medicine caused harm, but it creates a safety record that can be assessed scientifically.
Why This Matters for Patients Using Ayurveda with Modern Medicines
Many patients do not tell their physician that they are taking Ayurveda. Many also do not tell their Ayurveda doctor about all prescription medicines. This gap can increase the risk of missed interactions, duplicate effects or delayed recognition of side effects.
The safer approach is coordinated care. Ayurveda and modern medicine do not have to be treated as separate worlds when a patient is using both. A proper safety review can protect the patient while allowing appropriate Ayurvedic treatment to continue.
Ayurveda pharmacovigilance supports this responsible model. It encourages patient-specific prescribing, medicine-quality assessment, dose discipline, adverse-event reporting and evidence-based monitoring. For chronic disease patients, this is not an optional extra. It is part of safe treatment.
FAQs
What is Ayurveda pharmacovigilance?
Ayurveda pharmacovigilance is the monitoring of suspected side effects, adverse reactions, product-quality issues and herb–drug interactions related to Ayurvedic medicines.
Why is Ayurveda pharmacovigilance important?
Ayurveda pharmacovigilance is important because many patients use Ayurvedic medicines along with diabetes, blood pressure, heart, cancer or autoimmune medicines. Monitoring helps reduce avoidable risk.
Can Ayurvedic medicines interact with modern medicines?
Yes. Some Ayurvedic herbs, extracts or herbo-mineral formulations may change the effect, metabolism or safety of prescription medicines. The risk depends on the formulation, dose, patient condition and drug involved.
Are herbo-mineral Ayurvedic medicines always unsafe?
No. Herbo-mineral medicines are not automatically unsafe, but they require proper processing, quality testing, correct prescription and monitoring. Product-specific evidence is important.
Are plant-only Ayurvedic medicines always safe?
No. Plant-only medicines can also cause reactions in some patients, especially when used in high doses, poor-quality products or unsuitable combinations.
Should patients stop modern medicines before starting Ayurveda?
No. Patients should not stop essential prescription medicines without medical advice. The safer approach is to share the complete medicine list with the Ayurveda doctor and treating physician.
What should patients report before starting Ayurvedic treatment?
Patients should report all prescription medicines, supplements, allergies, liver or kidney disease, cancer treatment, pregnancy, blood-thinner use and previous drug reactions.
What symptoms need urgent attention during Ayurvedic treatment?
Breathing difficulty, facial swelling, chest pain, fainting, yellow eyes, dark urine, severe vomiting, severe abdominal pain, reduced urination, seizures or sudden weakness need urgent medical care.
Where can adverse reactions to Ayush medicines be reported in India?
Suspected adverse reactions related to Ayush medicines can be reported through India’s Ayush Suraksha platform or discussed with a qualified healthcare professional.
Does pharmacovigilance weaken trust in Ayurveda?
No. Pharmacovigilance strengthens trust in Ayurveda by supporting safer prescribing, better documentation, interaction assessment and evidence-based treatment monitoring.
References
[1] Central Council for Research in Ayurvedic Sciences, Central Ayurveda Research Institute, Bengaluru. (2026). National symposium on pharmacovigilance in Ayurveda, 17–18 September 2026 [Symposium circular]. Central Council for Research in Ayurvedic Sciences. https://ccras.nic.in/wp-content/uploads/2026/06/29052006-Pharmacovigilance-CARI-Bengaluru-.pdf
[2] ET Bureau. (2026, September 20). Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS. The Economic Times. https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/ayurveda-needs-stronger-evidence-safety-monitoring-for-market-adoption-says-ccras/articleshow/134366919.cms
[3] World Health Organization. (2004). WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. World Health Organization. https://www.who.int/publications/i/item/9241592214
[4] World Health Organization. (2021). Key technical issues of herbal medicines with reference to interaction with other medicines. World Health Organization. https://www.who.int/publications/i/item/9789240019140
[5] World Health Organization. (2019). Medication safety in polypharmacy: Technical report. World Health Organization. https://www.who.int/publications/i/item/medication-safety-in-polypharmacy-technical-report
[6] Hussaarts, K. G. A. M., Hurkmans, D. P., Oomen-de Hoop, E., van Harten, L. J., Berghuis, S., van Alphen, R. J., Spierings, L. E. A., van Rossum-Schornagel, Q. C., Vastbinder, M. B., van Schaik, R. H. N., van Gelder, T., Jager, A., van Leeuwen, R. W. F., & Mathijssen, R. H. J. (2019). Impact of curcumin, with or without piperine, on the pharmacokinetics of tamoxifen. Cancers, 11(3), 403. https://pubmed.ncbi.nlm.nih.gov/30909499/
[7] Saper, R. B., Phillips, R. S., Sehgal, A., Khouri, N., Davis, R. B., Paquin, J., Thuppil, V., & Kales, S. N. (2008). Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA, 300(8), 915–923. https://pubmed.ncbi.nlm.nih.gov/18728265/
[8] World Health Organization. (2007). WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. World Health Organization. https://www.who.int/publications/i/item/9789241594448
[9] Björnsson, H. K., Björnsson, E. S., Avula, B., Khan, I. A., Jonasson, J. G., Ghabril, M., Hayashi, P. H., & Navarro, V. J. (2020). Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver International, 40(4), 825–829. https://pubmed.ncbi.nlm.nih.gov/31991029/
[10] Press Information Bureau, Government of India. (2025, May 30). Ayush Suraksha portal launched to address issues of misleading advertisements and adverse drug reaction. Ministry of Ayush. https://www.pib.gov.in/PressReleasePage.aspx?PRID=2132705
